Bruton's tyrosine kinase (BTK) kinase is a member of the TEC kinase family and is a key regulator of the B-cell receptor (BCR)-mediated signaling pathway. It is important for B-cell maturation, proliferation, survival and metastasis. Pharmacological inhibition of BTK is clinically effective against a variety of B-cell malignances, such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and activated B-cell-diffuse large B-cell lymphoma. MNK kinase is one of the key downstream regulators in the RAF-MEK-ERK signaling pathway and controls protein synthesis via regulating the activity of eIF4E. Inhibition of MNK activity has been observed to moderately inhibit the proliferation of AML cells. Through a structure-based drug-design approach, we have discovered a selective and potent BTK/MNK dual kinase inhibitor (QL-X-138), which exhibits covalent binding to BTK and noncovalent binding to MNK. Compared with the BTK kinase inhibitor (PCI-32765) and the MNK kinase inhibitor (cercosporamide), QL-X-138 enhanced the antiproliferative efficacies in vitro against a variety of B-cell cancer cell lines, as well as AML and CLL primary patient cells, which respond moderately to BTK inhibitor in vitro. The agent can effectively arrest the growth of lymphoma and leukemia cells at the G0-G1 stage and can induce strong apoptotic cell death. These primary results demonstrate that simultaneous inhibition of BTK and MNK kinase activity might be a new therapeutic strategy for B-cell malignances.
INTRODUCTION
Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase discovered in the early 1990s during investigation of inherited immunodeficiency disease X-linked agammaglobulinaemia.
1,2 It belongs to the TEC tyrosine kinase family and is predominantly expressed in B cells. 3, 4 BTK kinase is a key element of B-cell receptor (BCR) signaling and has important roles in the regulation of B-cell survival, activation, proliferation and differentiation. [5] [6] [7] Upon BCR activation, BTK kinase translocates to the membrane and gets phosphorylated by Src family kinases at Y551, followed by autophosphorylation at Y223, which in turn induces the activation of PLCγ and other signaling pathways, including PI3K/Akt/mTOR, Stat5 and NF-κB; however, conversely, activity of PI3K produces PIP3 required for BTK localization to the membrane and activation, thus suggesting interaction and cross-talk between signaling pathways. 4, 8 Defective BTK function has been linked to a variety of B-cell malignances, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Waldenstrom macroglobulinemia and multiple myeloma. 8 Pharmacological targeting of BTK kinase led to the discovery of the kinase inhibitor ibrutinib (PCI-32765), which has been clinically investigated for activity against CLL, MCL, Waldenstrom macroglobulinemia, activated B-cell-DLBCL and multiple myeloma and recently received regulatory approval for MCL and CLL. [9] [10] [11] [12] Recently, PCI-32765 also demonstrated beneficial effects in AML. 13 Other BTK inhibitors, such as GDC-0834 and HM-7124, are being clinically tested for activity in rheumatoid arthritis, and CC-292 and NO-774 are being tested against CLL. 12 Mitogen-activated protein kinase interacting kinase 1 and 2 (MNK1/2) are serine/threonine kinases ubiquitously expressed in mammalian cells.
14 MNK kinases are substrates of ERK and p38 kinases and regulate translation through phosphorylation of serine 209 of eukaryotic initiation factor 4E (eIF4E). eIF4E is a key regulator of translational processes that can induce cell transformation by augmenting translation of proliferation-and survivalpromoting proteins such as cyclins, c-Myc and Bcl-xL. 15, 16 Elevated eIF4E levels/activity have been shown to promote tumor development and progression in vivo and are observed in about 30% cancers, including those of the colon, breast, lung and also Hodgkin's lymphomas. [17] [18] [19] Studies show that MNK-mediated phosphorylation of S209 is essential for eIF4E's role in oncogenic transformation, but not for normal physiological processes; therefore, pharmacological inhibition of MNKs may be an attractive approach for cancer therapy.
14 MNK kinase inhibitors, such as CGP57380 and cercosporamide, can block MNK-mediated eIF4E phosphorylation and induce dose-dependent inhibition of proliferation, as well as increased apoptosis in HCT-116 and B16 cell lines. 20 Recently, cercosporamide was shown to exhibit antitumor activity in MV4-11 AML models. In addition, inhibition of MNK kinase has been demonstrated to be effective against the blast crisis stage of chronic myeloid leukemia. 21 Collectively, these findings suggest that pharmacological blockage of MNK may be beneficial for some B-cell-mediated malignances.
Despite the significant clinical efficacy of BTK inhibitors and preclinical effects observed with MNK inhibitors in B-cell-mediated malignances, both of them have been combined with other agents to enhance overall efficacy. 22, 23 Given the fact that BTK kinase-mediated BCR signaling cross talks with PI3K/Akt/mTOR signaling and MNK kinase-mediated eIF4E signaling is downstream of RAS/RAF/MEK/ERK, as well as PI3K/Akt/mTOR signaling, we hypothesized that simultaneously inhibiting BTK and MNKs kinases would exert combinatorial efficacies than targeting these kinases individually. Here we present the first potent and selective BTK/MNK dual kinase inhibitor, QL-X-138, through a rational drugdesign approach. We demonstrate that the dual inhibition leads to induction of enhanced antiproliferation effects in lymphomas, leukemia cell lines in vitro and CLL/AML primary patient cells, which respond moderately to single BTK or MNK inhibitors. Our findings introduce a novel multitargeted treatment approach for B-cell malignancies.
MATERIALS AND METHODS

Chemical reagents
QL-X-138 was synthesized in the lab with the procedure provided in the Supplementary Materials. PCI-32765 was purchased from Chemexpress Inc. Shanghai, China. Cercosporamide was purchased from Tocris Bioscience (Bristol, UK).
Cell lines
The human AML lines, OCI-AML3, SKM-1, NOMO-1 and NB4 were obtained from Dr Gary Gilliland. HEL cells were purchased from the American Type Culture Collection (Manassas, VA, USA). The human AML-derived, FLT3-ITDexpressing line, MOLM14, was provided to us by Dr Scott Armstrong, Dana Farber Cancer Institute, Boston, MA, USA. The human ALL cell lines, NALM6 (pre-B) were generous gifts from Dr Thomas Look and Dr David Weinstock, respectively. HEL, NOMO-1, NB4, SKM-1 and NALM6 cells were cultured with 5% CO 2 at 37°C, at a concentration of 2 × 10 5 to 5 × 10 5 in RPMI (Mediatech, Inc., Herndon, VA, USA) with 10% fetal bovine serum (FBS) and supplemented with 2% L-glutamine and 1% penicillin/streptomycin. OCI-AML3 cells were cultured in alpha MEM media (Mediatech) with 10% FBS and supplemented with 2% L-glutamine and 1% penicillin/streptomycin. RV-1, HCT116, HeLa and DU145 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM; Corning, Manassas, VA, USA) and all other cell lines used in this paper were grown in RPMI 1640 (Corning), both containing 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 1% penicillin-streptomycin (Gibco, BRL).
We have authenticated the following cell lines through cell line short tandem repeat (STR) profiling (DDC Medical, Fairfield, OH, USA): MOLM14, NOMO-1, HEL, SKM-1, OCI-AML3, and NB4. All cell lines matched 480% with lines listed in the DSMZ Cell Line Bank STR Profile Information.
Primary cells
Mononuclear cells were isolated from AML patients by density-gradient centrifugation through Ficoll-Plaque Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden) at 2000 r.p.m. for 30 min, followed by two washes in 1 × phosphate-buffered saline. Freeze-thawed cells were then cultured in liquid culture (DMEM, supplemented with 20% FBS). All blood and bone marrow samples from AML patients were obtained through written consent under approval of the Dana-Farber Cancer Institute Institutional Review Board. The ethics committees approved the consent procedure.
Peripheral blood mononuclear cells from individuals with CLL were isolated by density centrifugation through Ficoll and frozen for each subject. Those subjects with low white counts whose CLL cell purity was expected to be o85% underwent B-cell isolation using RosetteSep (STEMCELL Technologies, Vancouver, BC, Canada). The protocol was approved by the Dana-Farber Harvard Cancer Center Institutional Review Board and all subjects signed written informed consent prior to participation. Antibodies P-BTK Y551 (#441355) antibody was obtained from Invitrogen (Carlsbad, CA, USA). eIF4E antibody was obtained from BD Biosciences (San Jose, CA, USA). P-BTK Y223 (#5082), BTK (#3533), peIF4E Ser209 (#9741), P-P70S6K Thr389 (#9234), P70-S6K (#2708), P-4EBP1 Thr37/46 (#2855), 4EBP1(#9644), P-SYK Thr352 (#2717), SYK(#2712), P-MNK Thr197/202(#2111), MNK (#2195), p-PLCγ2 Y1217 (#3871), PLCγ2(#3872), PARP(#9542), and Caspase 3(#9662) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA).
EGFR (T790M) crystallography complexes with QL-X-138
Construct preparation, protein expression and purification of EGFR 696-1022 T790M were done as previously reported. 24 The EGFR 696-1022 T790M crystals were grown in the absence of QL-X-138 by hanging drop vapor diffusion. The reservoir solution for crystallization was 0.1 M HEPES (pH 7.5), 21% PEG6000, 0.3 M NaCl, and 5 mM tris (2-carboxyethyl)-phosphine. The compound was then incorporated by soaking the crystals in the soaking buffer (the reservoir solution was supplemented with 1.0 mM QL-X-138) overnight. The complex crystals were flash-frozen in the cryoprotectant that was a 3:1 mixture of the soaking buffer and ethylene glycol. The diffraction data were collected at APS 24-ID-C at 100 K and were processed using HKL-3000. 25 The structure was solved by Fourier synthesis using the previously reported T790M/WZ-4002 structure (PDB 3IKA) without the compound, water molecules and ions as the starting model. The structure was then refined using Phenix and Coot. 26, 27 The inhibitor was modeled into the closely fitting positive Fo-Fc electron density and then included in the following refinement and fitting cycles. Topology and parameter files for the inhibitor were generated using PRODRG. 28 Data collection and structure refinement statistics were listed in Supplementary Table 2. BTK and MNK2 docking Docking QL-X-138 to BTK and MNK2 was performed with Autodock 4.0. PDB 3GEN and 2HW7 (Molecular Graphics Lab, La Jolla, CA, USA) were chosen as the model structures for BTK and MNK2, respectively. QL-X-138 was constructed using online demo: CORINA. Then the grip map was set with the 56 × 56 × 56 points and the space of 0.375 angstrom. The other parameters were used with the default values. Finally, the docket conformations were sorted by the binding energy.
IP kinase assay (BTK, MNK and mTORC1)
BTK IP kinase assay Generating BTK stable cell lines: Retroviral expression vectors were constructed by inserting wild-type (wt) and C481S mutant BTK coding regions into a pMSCV-puro vector (Clontech, Mountain View, CA, USA) that was modified by inserting a 3XFLAG sequence at the 3′ end of the multicloning sites. Retroviruses of BTK-WT-FLAG and BTK-MT-FLAG were packaged by transfecting the plasmids with two helper plasmids into 293T cells using Fugene 6 (Roche, Madison, WI, USA). After 48 h, the medium of 293T cells was replaced with DMEM medium containing 1 μg/ml of puromycin for 48 h. Then cells were maintained in DMEM medium containing 1 μg/ml of puromycin.
Kinase assay: The serially diluted QL-X-138 was added to the BTK kinase. After a 30-min incubation at room temperature, ATP (final concentration: 20 μM) was added and incubated for 20 min at 37°C. The reactions were stopped by addition of 5 × sample buffer. Then the phosphorylation of BTK was detected by western blot using a pBTK Y551 antibody (BD, San Diego, CA, USA).
MNK IP kinase assay
Generating MNK1/2 stable cell lines: Retroviral expression vectors were constructed by inserting full-length wt and MNK1(C190S), MNK2 (C225S) coding regions into a pMSCV-puro vector (Clontech) that was modified by inserting a 3XFLAG sequence at the 3′ end of the multicloning sites. Retroviruses of MNK1/2-WT-FLAG and MNK1/2-MT-FLAG were packaged by transfecting the plasmids with two helper plasmids into 293T cells using Fugene 6 (Roche). After 48 h, the medium of 293T cells was replaced with DMEM medium containing 1 μg/ml of puromycin for 48 h. Cells were then maintained in DMEM medium containing 1 μg/ml of puromycin.
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Expression of eIF4E: The eIF4E cDNA fragment encoding the full-length of eIF4E was cloned into a pTriEx vector (Novagen, San Diego, CA, USA), in frame with an N-terminal histidine tag for bacterial expression. The protein was expressed in Escherichia coli cells with an overall yield of 2-5 mg/l.
Kinase assay: The reaction system contained MNK wt or mutant and eIF4E. Serial dilutions of QL-X-138 were added to the protein. After a 30-min incubation at room temperature, ATP (final concentration: 20 μM) was added and incubated for 30 min at 37°C. The reactions were stopped by addition of 5 × sample buffer. Then, the phosphorylation of eIF4E was detected by western blot using peIF4E Ser209 antibody (CST).
mTORC1 IP kinase assay. The HEK293T-Raptor cell line, which stably expresses Raptor-FLAG fusion protein, was cultured in DMEM (Corning). After 48 h, the cells were collected and lysed and Raptor − mTORC1 complex was purified by ANTI-FLAG M2 Affinity Gel (Sigma, St Louis, MO, USA). The substrate 4EBP1 was expressed in E. coli with 6 × His tag and purified by Ni-Resin (GE, Piscataway, NJ, USA). The kinase reaction was performed by incubation of serially diluted QL-X-138 with mTORC1 and 4EBP1. After a 30-min incubation at room temperature, ATP was added and incubated for another 30 min at 37°C. The reactions were stopped by addition of 5 × sample buffer. Then the phosphorylation of 4EBP1 was detected by western blot using P-4EBP1 Thr37/46 antibody (CST, Danvers, MA, USA).
Cell culture and antiproliferation assay Cells were grown in 96-well culture plates (2500-3000/well) for 12 h before compounds of various concentrations were added. Cell proliferation was determined after treatment with compounds for 72 h. Cell Titer-Glo assays were performed according to the manufacturer's instructions; and luminescence was measured in a multilabel reader (Envision, PerkinElmer, Hopkinton, MA, USA). Data were normalized to control groups (dimethyl sulfoxide) and represented by the mean of three independent measurements with standard error o20%. GI 50 values were calculated using Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Signaling pathway analysis
Ramos cells were cultured in 10% FBS-containing RPMI and OCI-AML3 cells were cultured in 10% FBS-containing alpha-MEM medium. The serially diluted QL-X-138 was added to cells for 4 h. The cells were collected and lysed, and cell lysates were analyzed by western blotting.
Apoptosis
Ramos and OCI-AML3 cells were cultured in 10% FBS-containing alpha-MEM medium. The serially diluted QL-X-138 was added to cells for 16/24/48 h. Then, apoptosis of OCI-AML3 cells and Ramos cells were detected by western blotting using PARP and Caspase 3 antibodies (CST).
Cell cycle analysis
Ramos cells were cultured in 10% FBS-containing RPMI and OCI-AML3 cells were cultured in 10% FBS-containing alpha-MEM medium with QL-X-138 at concentrations of 0.5 and 1 μM. After 24, 48 and 72 h, cells were collected and stained with PI/RNase staining buffer (BD Pharmingen, Bristol, UK) and cell cycle progression of cells was analyzed using FACS Calibur (BD).
CLL and AML primary patient cells: proliferation assay
Mononuclear cells were isolated from CLL and AML patients. Cells were tested in liquid culture (DMEM, supplemented with 20% FBS) in the presence of different concentrations of QL-X-138 or PCI-32765. The trypan blue exclusion assay was used for quantification of cells for seeding for CellTiter Glo assays (Promega, Madison, WI, USA). The CellTiter Glo assay was used for proliferation studies and carried out according to manufacturer's instructions. Cell viability is reported as percentages of control (untreated) cells.
RESULTS
Rational design of BTK/MNK dual inhibitor QL-X-138
On the basis of inspection of the available X-ray structures of BTK (PDB ID: 3GEN) and MNK1/2 (PDB ID: 2HW6/2HW7) kinases, we envisioned that a suitably designed inhibitor could potentially target two distinct cysteine residues in the ATP-binding sites of both kinases. BTK kinase possesses a cysteine (C481) in the hinge binding area that is covalently modified by irreversible inhibitors such as PCI-32765 and AVL-292. 29, 30 MNK1/2 possesses a cysteine (C190/C225), which is located before the highly conserved DFG(D) motif that marks the start of the kinase activation loop. 31 We aimed to develop an inhibitor bearing a mobile acrylamide electrophile that could form a covalent bond with either cysteine residue. (Figure 1a )
In order to explore this possibility we searched our kinase inhibitor database to identify a scaffold that could provide a suitable platform to incorporate an electrophilic 'warhead,' which led to our previously developed tricyclic mTOR inhibitor Torin2.
32
Torin2 is an exceptionally potent biochemical inhibitor of mTOR (IC 50 = 250 pM) but also less potently inhibits MNK2 (IC 50 = 620 nM), with no apparent activity against MNK1 and BTK kinases. Molecular modeling suggested that replacing the CF 3 group with an acrylamide group would provide an inhibitor with the ability to potentially form a covalent bond with the cysteine in BTK or MNK1 and MNK2. We replaced the aminopyrimidine side chain of Torin2 with a pyrazole that previous results suggested would greatly diminish mTOR inhibitory potency (Figure 1b ) An IP kinase assay with BTK kinase demonstrated that QL-X-138 exhibits an IC 50 of 9.4 nM in a fixed time-point assay with no apparent inhibitory activity against BTKC481S, which indicates that QL-X-138 might be an irreversible inhibitor of BTK kinase (Figure 1c and Supplementary Figure 1) . In order to further confirm this irreversible binding mode, we made a reversible version of QL-X-138 by replacing the acrylamide with a propionamide (QL-X-138R; Supplementary Figure 2A ). An IP kinase assay demonstrated that QL-X-138R completely lost its inhibitory activity against both the wt BTK and BTK C481S mutant, which further supports the notion that QL-X-138 is a covalent inhibitor of BTK kinase (Supplementary Figure 2B) . In addition, we performed mass spectrum study and detected the site-specific labeling of BTK Cys481 by QL-X-138, which confirmed this covalent binding (Supplementary Figure 3) .
An IP kinase assay with MNK1 and MNK2 demonstrates that QL-X-138 can inhibit these kinases with an IC 50 of 107.4 and 26 nM, respectively, which can be rescued up to a concentration of 3 μM using mutated MNK1(C190S) and MNK2(C225S) kinases (Figure 1d and Supplementary Figure 4) . However, the noncovalent analog, QL-X-138R, is only twofold less potent as a biochemical inhibitor of MNK1 and MNK2 relative to QL-X-138, demonstrating that this scaffold has excellent noncovalent affinity (Supplementary Figure 5A) . To further investigate whether QL-X-138 is a covalent MNK2 inhibitor, we performed cellular 'washout' experiments and evaluated the kinetics of the recovery of eIF4E Ser209 phosphorylation. The results show that eIF4E phosphorylation is restored quickly (Supplementary Figure 5B) . Given the fact that reversible inhibitor binding activity usually is more sensitive to ATP concentrations, we then conducted an ATP competition IP kinase assay with MNK2 kinase. The result showed that with higher ATP concentrations, the inhibitory activity of QL-X-138 against MNK2 was significantly decreased (an over 30-fold difference was observed between 500 versus 10 μM ATP; Supplementary Figure 5C ) Collectively these experiments suggest that QL-X-138 is a noncovalent inhibitor of MNK1/2 kinases. These results demonstrate that we have achieved the development of a potent dual BTK/MNK kinase inhibitor containing dual binding modes, which targets BTK kinase through covalent binding and targets MNK1/2 kinase using reversible binding.
Selectivity and binding mode illustration of QL-X-138
In order to further characterize the selectivity profile of QL-X-138, we then subjected QL-X-138 to a kinome selectivity analysis using DiscoveRx's KinomeScan technology at a concentration of 1 μM.
QL-X-138 exhibits good overall kinase selectivity with a Score (1) of 0.01. 33 QL-X-138 exhibited strong binding to BTK and JAK3 kinases (0.85 and 0% activity remaining; Figure 1e and Supplementary Table 1 ). Enzymatic assays (Invitrogen SelectScreen, Invitrogen, Camarillo, CA, USA) confirmed potent inhibition of BTK (IC 50 of 8 nM) and JAK3 (IC 50 of 55.7 nM; Supplementary Table 2) . However, further analysis with Tel-fused JAK3-Ba/F3 cells showed that QL-X-138 did not strongly inhibit the JAK3 kinase in the cellular context (GI 50 410 μM), which suggests that the biochemical JAK3 inhibitory activity does not predict activity in a cellular assay for this compound series (Supplementary Table 3 ). On the basis of the fact that EGFR also shares a similar cysteine residue in the hinge binding area, we also examined the activity of QL-X-138 against EGFR and the EGFR T790M mutant. However, we did not observe strong binding according to the KinomeScan profiling data (56 and 2% activity remaining, Supplementary Table 1) . QL-X-138 exhibited 597 and 137 nM IC 50 , respectively, against EGFR wt and EGFR (T790M) mutant in a biochemical assay, however, these potencies did not translate into the cellular assay again when using TEL transfusion kinase BaF3 isogenic cell lines (Supplementary Table 3 ). Since QL-X-138 was originally derived from an mTOR inhibitor, we further tested QL-X-138 in an mTORC1 IP kinase assay as well as in a cellular assay using HeLa cells. Results confirmed that QL-X-138 lacks mTOR inhibitory activity, both in vitro and in the cellular assay at concentrations below 1 μM (Supplementary Figure 6A and  B) . Interestingly, QL-X-138 did not strongly target MNKs in KinomeScan panels, which is not consistent with the IP in vitro kinase assay. It is possible that this was due to limitations of the binding assay format or special features of the MNK kinase that favors DFD-out conformation. 14 In order to further elucidate the binding mode of QL-X-138, we attempted to crystalize the inhibitor in complex with the targeted kinases. Although we were unable to obtain an X-ray crystal of QL-X-138 bound to BTK or MNK, we instead obtained an EGFR (T790M) protein complex with the inhibitor (PDB ID: 4WD5 and 
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Supplementary Table 4 ; Figure 2a ). The structure shows that QL-X-138 forms a hinge binding with Met793 and the acrylamide forms a covalent binding with Cys797, which is located in a position equivalent to Cys481 in the BTK kinase. 34 A molecular modeling study with the BTK kinase X-ray structure (PDB: 3GEN) showed that QL-X-138 can form a hinge binding with Met477 and a hydrogen bond with Lys430, and can form a covalent bond with Cys481 with its warhead acrylamide (Figure 2b) . A docking study of QL-X-138 with MNK2 kinase X-ray structure (PDB ID: 2HW7) suggests that the inhibitor may form a hinge hydrogen bond with Met162 and a salt-bridged hydrogen bond through its pyrazole ring with Gly129 and Asp226. Our initial design involved projecting the acrylamide 'warhead' to rotate toward the inside of the ATP binding pocket and forming a covalent bond with Cys225 (Figure 2c) . However, the biological data suggest that we have not achieved covalent binding to Cys225. A detailed molecular modeling study suggests that Glu209 may make a hydrogen bond with amide NH in the 'warhead' moiety, which helps to project the carbonyl group toward Cys225 and form another hydrogen bond. (Figure 2d ) These two hydrogen bonds force the double bond to rotate outward against Cys225 and hence prevent the covalent bond formation.
QL-X-138 exhibits greater antiproliferation activity against lymphoma and leukemia cell lines We surveyed the antiproliferative activity of QL-X-138 against a panel of different cancer cell lines. The results showed that for the BTK kinase inhibitor sensitive activated B-cell-DLBCL cell line TMD8, PCI-32765 demonstrated superior potencies (GI 50 : 0.002 μM) than QL-X-138 (GI 50 : 0.31 μM), which might reflect its stronger activities against BTK kinase (IC 50 : 0.5 nM versus 8 nM) 34 (Table 1 ). For the cell lines that do not express BTK kinase, such as RV-1, DU-145, HCT-116, HeLa and K562, QL-X-138 did not exhibit apparent antiproliferation activity at concentrations below 10 μM. For those cell lines that have been validated for expression of BTK kinase but moderately sensitive to PCI-32765, such as Burkitt lymphoma cell line (Ramos), DLBCL cell line (U2932), AML cell lines (MOLM14, OCI-AML3, SKM-1, NB4, HEL, NOMO-1 and U937) and an ALL cell line (NALM6), QL-X-138 exhibited a GI 50 of around 1 μM and is generally more potent than selective BTK and MNK inhibitor. This indicates that dual inhibition of MNK and BTK kinase may translate into higher antiproliferative activity as compared with inhibition of each individual kinase alone in the BTK kinase inhibitor moderate sensitive cell lines. This was further validated by an experiment showing that a close analog of QL-X-138, the previously published BMX kinase inhibitor (BMX-IN-1), which possesses similar BTK kinase activity to QL-X-138 but no apparent MNK kinase activity, exhibits weaker antiproliferation activity in comparison with QL-X-138 (Liu et al.;
35 Supplementary Table 5) . We also conducted a combination experiment to examine the proliferation inhibitory activity of dual inhibition of BTK and MNK kinase activity. Combining the BTK kinase inhibitor, PCI-32765 and Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma.
MNK kinase inhibitor, cercosporamide, indeed, led to a positive combination effect against the AML cell lines, NB4 and U937 (Supplementary Figure 7) .
QL-X-138 blocks BTK-and MNK-mediated signaling
We next investigated the efficacy of QL-X-138 against the relevant signaling pathways in the cellular context for those cell lines that exhibited moderate sensitivity to BTK inhibitors. For the Burkitt lymphoma Ramos cell line, QL-X-138 significantly suppressed BTK autophosphorylation of Y223 (EC 50 : 11 nM), but did not affect Y551 as previously observed for PCI-32765 (Honigberg et al.; 34 Figure 3a and Supplementary Figure 8) . In addition, both QL-X-138 and PCI-32765 strongly blocked phosphorylation of the BTK downstream target PLCγ2 Y1217 (EC 50 : 57 nM). QL-X-138, PCI-32765 and cercosporamide did not affect MNK phosphorylation, which is consistent with what has been previously reported for cercosporamide. 20 However, both QL-X-138 and cercosporamide suppressed the phosphorylation of the MNK downstream target eIF4E S209 at a concentration of 1 μM. QL-X-138 also affected mTOR signaling pathway mediators, S6K and 4EBP1, which is not consistent with the observed EC 50 values observed from the non-BTK expressing cell line, HeLa (Supplementary Figure 6B) . This suggests that mTOR signaling is downstream of the BTK-mediated signaling pathway and the weak inhibitory activity of QL-X-138 against mTOR may have been strengthened in this case. Similar results were observed for these drugs against the AML cell lines (OCI-AML3 and U937) and DLBCL cell lines (U2932). This suggests that the dual inhibitory effect of QL-X-138 is not cell line specific (Figures 3b-d and Supplementary Figure 8) . Interestingly, for Ramos, OCI-AML-3 and U2932 cell lines, we observed hyperactivation of pMNK T197/202 at concentrations higher than 1 μM, despite the down-regulation of peIF4E at the same time point; this suggests that a negative-feedback mechanism might exist for the signaling as has been observed previously for mTOR inhibition and consequent re-activation of MNK kinase 36, 37 (Supplementary Figure 9) . QL-X-138 arrests cell cycle progression and strongly induces apoptosis We then investigated the effects of QL-X-138 on the cell cycle progression. For the Ramos cell line, QL-X-138 significantly inhibited cell cycle progression at G0/G1 in a dose-dependent manner at 24 h (Figure 4a and Supplementary Figure 10) , whereas for the AML cell lines (OCI-AML-3 and U937) and DLBCL cell line U2932, QL-X-138 did not cause cell cycle arrest at concentrations up to 1 μM until after 72 h of treatment. In Ramos cells, QL-X-138 strongly induced apoptosis at a concentration of 1 μM at 8 h, while with a longer drug exposure (24 h), a concentration of 300 nM was sufficient to induce apoptosis (Figure 4b ). QL-X-138 induced apoptosis of OCI-AML3 cells at a higher concentration (5 μM) after 48 h of treatment (Figure 4c) . Similarly, induction of apoptosis by QL-X-138 in U2932 cells was observed following 48 h treatment, starting from the concentration of 500 nM (Figure 4d) . However, even with 72 h treatment, U937 cells did not undergo druginduced apoptosis (Figure 4e) . Fluorescence-activated cell sorting analysis also revealed induction of apoptosis of Ramos and U2932 cells; however, no apoptosis was observed for OCI-AML-3 and U937 cells; this is consistent with cell cycle results and debris observed at subG0 in these cell lines (Supplementary Figure 11) .
QL-X-138 inhibits the proliferation of primary CLL and AML patient cells Both PCI-32765 and cercosporamide have shown moderate antiproliferative activity against CLL and AML primary patient cells (Supplementary Table 6) . 13, 21 In order to similarly evaluate the potential clinical efficacy of QL-X-138, we tested the drug against a panel of CLL and AML patient cells. The results generally demonstrate a stronger effect of QL-X-138 over PCI-32765 and cercosporamide as single agents (Table 2) . Moreover, colony formation of normal bone marrow cells was not inhibited by QL-X-138 at a concentration of 1 μM, which suggests a moderate therapeutic window for the further drug development (Supplementary Figure 12) .
DISCUSSION
The clinical success of PCI-32765 against CLL and MCL has proven BTK kinase to be a valuable drug discovery target for a variety of BCR constitutively activated B-cell malignances. In addition, an increasing amount of preclinical data has suggested that the BTK kinase inhibitor may be effective against AML and activated B-cell-DLBCL. 12 However, there has been some controversy regarding whether or not BTK has a critical role in these diseases, like BCR-ABL does in chronic myeloid leukemia, given the fact that BCR signaling. 4 Hsp90 inhibitors and other agents have been shown to potentiate the efficacy of BTK inhibitors and signaling pathway inhibitors such as those targeting JAK2. 8, 38 These studies have made development of a multitargeted BTK inhibitor an attractive approach for more effectively treating BCR-mediated cancers. 39 Both BTK inhibitors and MNK inhibitors have been shown to be effective against leukemia cells. BTK is generally upstream of the PI3K/Akt/mTOR signaling pathway, although BTK is conversely influenced by PI3K/Akt/mTOR signaling suggesting cross-talk and interaction between signaling pathways. 8 BTK links to the NFκB-mediated transcription signaling pathway via PLCγ. MNK is downstream of the RAF-MEK-ERK signaling pathway and controls the transcription factor eIF4E, which is also linked to the mTOR signaling pathway. 8 Therefore, combinatorial inhibition of BTK and MNK kinase activity seems a feasible way to obtain greater efficacy than in cell lines that exhibit moderate sensitivity to selective BTK inhibitors. Nevertheless, there are cellular models where dual inhibition of BTK/MNK kinase may not result in enhanced antiproliferative activity, as is the case in TMD8 cells where PCI-32765 exhibits comparable potency.
The rational design of multiple targeted drugs is usually challenging considering the difficulty of achieving a high level of selectivity, however, it is an attractive approach to achieving improved efficacy against oncogene-driven diseases. [40] [41] [42] Our study again exemplifies that it is feasible to achieve a selective multiple targeted inhibitor through a rational design approach. One clear challenge for multitargeted kinase inhibitors is that it is much more difficult to ascribe the pharmacological effects of the inhibitor to a particular kinase target. Although we have characterized the effects of QL-X-138 as a dual inhibitor of BTK and MNK, we cannot exclude the possibility that other targets, including nonkinase targets, could contribute to the pharmacology exhibited by this inhibitor.
We have successfully developed the first highly potent and relatively selective dual BTK/MNK inhibitor, which exhibits enhanced antiproliferative activity in in vitro cell lines model and primary patient-derived AML and CLL cells. This provides a proof of concept that dual inhibition of BTK/MNK might benefit those cells that moderately respond to selective and potent BTK inhibitor. However, the poor pharmacokinetic properties of this compounds limits its application in the animal study and require further medicinal chemistry effort to improve its drug-like properties. Therefore, QL-X-138 can serve as a useful cellular probe for further investigation of mechanisms underlying the development and progression of BTK-and MNK-mediated cancers, and provides a useful chemical starting point for developing future clinical candidates bearing this inhibitory profile.
